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Abstract
Background: The safety of the immune complexes composed of yeast-derived hepatitis B surface antigen (HBsAg) and
antibodies (abbreviated as YIC) among healthy adults and chronic hepatitis B patients has been proved in phase I and phase
IIa trial. A larger number of patients for study of dosage and efficacy are therefore needed.
Methods and Principal Findings: Two hundred forty two HBeAg-positive chronic hepatitis B patients were immunized with
six injections of either 30 mg YIC, 60 mg of YIC or alum adjuvant as placebo at four-week intervals under code. HBV markers
and HBV DNA were monitored during immunization and 24 weeks after the completion of immunization. The primary
endpoint was defined as loss of HBeAg, or presence of anti-HBe antibody or suppression of HBV DNA, while the secondary
endpoint was both HBeAg seroconversion and suppression of HBV DNA. Statistical significance was not reached in primary
endpoints four weeks after the end of treatment among three groups, however, at the end of follow-up, HBeAg sero-
conversion rate was 21.8%(17/78) and 9% (7/78) in the 60 mg YIC and placebo groups respectively (p=0.03), with 95%
confidence intervals at 1.5% to 24.1%. Using generalized estimating equations (GEEs) model, a significant difference of
group effects was found between 60 mg YIC and the placebo groups in terms of the primary endpoint. Eleven serious
adverse events occurred, which were 5.1%, 3.6%, and 5.0% in the placebo, 30 mg YIC and 60 mg YIC groups respectively
(p.0.05).
Conclusions: Though statistical differences in the preset primary and secondary endpoints among the three groups were
not reached, a late and promising HBeAg seroconversion effect was shown in the 60 mg YIC immunized regimen. By
increasing the number of patients and injections, the therapeutic efficacy of YIC in chronic hepatitis B patients will be
further evaluated.
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Introduction
According to the World Health Organization, there are 350
million people worldwide, who are chronically infected with HBV.
Prolonged chronic hepatitis B results in the development of liver
cirrhosis, liver failure, or hepatocellular carcinoma[1]. The
pathogenesis of HBV in chronically infected patients has been
well- studied and reviewed. Lack of effective immune responses,
notably, defective cell-mediated immune responses (CD4, CD8
and NK cells, cytolytic responses) against HBV, defective dendritic
cell (DC) functions and imbalance of cytokine production have
been identified as the major mechanisms for virus persistence and
initiation of chronic liver disease [2,3,4,5,6]. Effective host
immune responses are crucial to terminate viral persistence. To
overcome the defects in immune responses, various therapeutic
measures have been designed to boost effective host immune
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of antigen and antibodies have long been used to induce potent
antibody responses against microbial proteins and other proteins
in animals [14]. Whether IC can be used for therapeutic treatment
of viral hepatitis B patients has been questioned because
circulating immune complexes (CIC) have been found in some
chronic hepatitis B patients [15]. We hypothesized that the crucial
difference between CIC and the immune complexes composed of
yeast-derived hepatitis B surface antigen (HBsAg) and antibodies
(abbreviated as YIC) used in this study is that, in CIC, the anti-
HBs antibodies from the patient are of low affinity, which cannot
efficiently bind to HBsAg and clear the protein from the host. In
contrast, the anti-HBs used to produce YIC are generated from
healthy adults who were immunized multiple times with yeast-
derived recombinant HBsAg. Therefore, these are high affinity
antibodies that can combine efficiently with HBsAg [16]. When
YIC is administered via intramuscular injections, it served as an
immunogen to the host, and antigen presenting cells in the
immune tolerant host would be forced to uptake the HBsAg
complexed to its antibodies via the Fc receptors on antigen
presenting cells, and thereby leading to modified antigen
processing and presentation in the complex. This hypothesis has
been confirmed by our previous experimental studies in animal
models and in vitro experiments on human dendritic cells [17,18].
A recent preliminary study in a small number of chronic hepatitis
B patients showed that the therapeutic effect of YIC correlated
with both cytolytic and noncytolytic responses [19].Though
antiviral drugs are highly effective in inhibiting HBV replication,
emergence of drug resistance and rebound of virus replication
after withdrawal of drugs are major disadvantages for treatment of
persistent viral infections [20,21]. Conversely, vaccine therapy is
an inexpensive and promising approach for the treatment of
persistent viral infections [22,23].
To study the in vivo immunotherapeutic effects of YIC in
chronic hepatitis B patients, a double-blind, randomized, placebo-
controlled clinical study was conducted, and results are presented.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Immune complexes and placebo
Both the immune complexes and placebo used in this study
were manufactured by Beijing Institute of Vaccine and Biological
Products, and the Chinese Good manufacture practice (GMP)
regulation was followed. Each dose of 1 mL immune complexes
(YIC) consisted of either 30 or 60 mg of HBsAg complexed to
human anti-HBs immunoglobulin (HBIG) at an appropriate ratio
(described in US patent 6,221,664 B1 and European patent
913157), using alum as the adjuvant, which was a mixture of
KAl(SO4)2 and NaOH. The placebo contained 0.1% alum
identical to that being used in YIC as the adjuvant.
Study design
This double-blind, randomized, and placebo-controlled study
was conducted at 12 evaluation centers for the treatment of HBV,
which were certificated by the State Food and Drug Administra-
tion (SFDA), China. Prior to initiating the clinical trial, the
protocol of this study was submitted, registered, licensed and
approved by the SFDA, China (license number 2002L0038). The
trial was registered at WHO International Clinical Trials Registry
Platform. Final approval from the ethics committee at Ditan
hospital after ethical evaluating at each participating center was
completed in February 2005, and enrollment of patients was
initialed in March, 2005. Prior to enrollment, each patient signed
a written consent for participating in this trial.
The study was designed in a three-arm fashion. Eligible patients
were assigned to receive 30 mg YIC, 60 mg YIC or placebo in
blocks of 6 (two for the 30 mg YIC vaccine, two for the 60 mg YIC
vaccine, and two for the placebo group) through computer
generated random numbers on the label of study agent vial in
terms of recruiting sequence. An independent biostatistician was in
charge of the processing of randomization using SAS program
(SAS Institute Inc., Cary, NC, USA). All participants were
immunized with six intramuscular injections at 4- week intervals,
and followed for 24 weeks after the termination of immunization.
Serum samples were collected from each patient at baseline, 12th,
24th, 36th and 44th week after initial injection, and separated into
two vials. One vial of serum was used for routine biochemical and
hematological tests, such as ALT, AST, and was conducted
immediately at each evaluation center. Another vial serum was
storied at 270uC at each center and shipped to the reference lab
at Beijing Ditan Hospital at the end of study for assays of HBV
markers and virus load of all samples from all centers. The study
was designed by a chief clinical investigator in Ditan Hospital, and
was monitored by TigerMed, China, an independent Contract
Research Organization. The principles of good clinical practice
and clinical trial-related guidelines issued by SFDA were
implemented throughout the study.
Patients
Patients with chronic hepatitis B, aged 18–65 years old, who
were HBsAg and HBeAg positive for at least 6 months and who
were anti-HBe negative with an HBV viral load .100,000 copies/
mL and a serum ALT of two to ten times the upper limit of normal
value within four weeks before randomization were recruited at
each evaluation center. Exclusion criteria were co-infection with
hepatitis A, C, D and E virus, or HIV; taking antiviral, hepatotoxic
or immunosuppressive drugs or products within the preceding 6
months; other causes of liver disease; serious medical or psychiatric
illness; hepatic cirrhosis or AFP .100 ng/mL; abnormal serum
creatinine, thrombocyte count, hemaglobin or serum total
bilirubin; and pregnancy.
Assays
Routine biochemical and hematological tests, such as ALT,
AST, were carried out at each evaluation center using automated
techniques available at each center.
At the end of study, all frozen serum samples from all enrolled
patients under code were transferred from all evaluation centers to
the reference lab at Beijing Ditan Hospital for assays of HBeAg,
anti-HBe and serum HBV DNA levels. Samples at all time points
were thawed and assayed using the same lot of reagents.
Sequential samples from one patient were tested on the same
day. Abbott EIA AxSYM (Abbott, Abbott Park, IL, USA) was
employed for HBsAg, HBeAg, and anti-HBe. According to
protocols provided by the manufacturer, positive and negative
cutoffs were calculated, with the positive and negative controls as
required by the diagnostic kits. Serum HBV DNA was quantified
by fluorescent PCR assay using the ABI equipment, and reagents
were from PiJi, Shenzhen Co, China, with a detection limit of 500
copies/mL.
Endpoints
The virologic response was assessed four weeks after the end of
treatment (week 24) and 24 weeks after the end of treatment (week
Therapeutic HB Vaccine
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the loss of HBeAg and the presence of anti-HBe antibody.
Suppression of HBV DNA was defined as the .2 log10 decrease
of viral load. The primary endpoint was defined as loss of HBeAg,
or presence of anti-HBe antibody or suppression of HBV DNA.
The secondary endpoint was designated as both HBeAg
seroconversion and suppression of HBV DNA.
Safety
All participants were observed for local reactions and systemic
symptoms through diary card and follow-up interview. The
causality of adverse events was determined by the clinical
investigators, and the criteria for severe adverse events were:
blood total bilirubin (TB) .3617.2 mmol/L), prolonged pro-
thrombin time (PTA) ,40%), and ALT levels elevated 10 times
higher than that of the baseline. The severity of adverse events was
classified as mild (easily tolerated; causing minimal discomfort; not
interfering normal everyday activities), moderate (Sufficiently
discomforting to interfere with normal everyday activities) and
severe (Prevents normal everyday activities). Safety analysis was
performed on all patients who underwent randomization and
received at least one dose of study agent.
Data management and statistical analysis
The sample size was calculated to ensure an adequate evaluation
of the primary endpoint. Based on the literatures and the results of
phase IIa trial, a sample size of 78 patients per arm could detect a
difference of primary response rate between 60 mg group, 30 mg
group and placebo group (response rate in 60 mg YIC group vs
placebo group,35%vs3%;and responserate in30 mg YICgroupvs
placebo group, 20% vs 3%) with a statistical power of 80% at the
0.05 level of significance, allowing for a dropout rate of 20%.
All data were double entered into custom-made data entry
programs. The data management programs included range and
consistency checks. An SAS program (SAS Institute Inc., Cary,
NC, USA) was applied for statistical analysis. Analysis was
conducted on all eligible patients according to the intent-to-treat
principle. HBV DNA was logarithmically transformed for analysis.
For binary data, the Chi square test, or Fisher’s exact test when
data were sparse, were employed. For dichotomous outcomes,
ANOVA was used.
Repeated measures analysis was performed using a generalized
estimating equations (GEEs) method to adjust the dependence
among repeated observations made on the same patient while
testing the group and time effects [24]. In the model, we included
the time effect as a class variable which used three indicator
variables. The indicator variable was defined by treating Week 44
as a baseline time. Similarly, the group effect was defined by using
two indicator variables, where the placebo group served as
baseline group. Since there were only four repeated measurements
(week 12, 24, 36, and 44), we applied the unstructured (UN)
working covariance matrix which provided robust estimation of
covariance to the structure. Since the ALT and HBV DNA are
crucial indicators for baseline assessment, adjustments were made
for group, baseline ALT and HBV DNA. A p-value ,0.05 (two-
tailed) was considered statistically significant.
Results
Baseline characteristics of enrolled patients
Three hundred and fifty four hepatitis B patients were evaluated
for the inclusion criteria. Of these, 242 patients were eligible and
assigned randomly to placebo, 30 mg YIC and 60 mg YIC groups
in a three-month period. Five patients were found ineligible during
the batch assay at the end of treatment (week 24) at the central
laboratory, and therefore were excluded from the intent-to-treat
analysis. Of 237 patients included in the analysis , 8 receiving
placebo, 5 receiving 30ug YIC, and 10 receiving 60ug YIC either
did not complete the treatment, did not complete the follow-up or
violated the protocol (Figure 1). No significant difference was
found in baseline characteristics among three groups (Table 1).
Kinetics of responses in patients
As shown in Table 2, a delayed response to YIC was observed
between 24 weeks and the end of follow-up. For intent-to-treat
analysis, at the end of follow-up, 31, 35 and 28 patients achieved the
primary endpoint, and 6, 7 and 14 patients reached the secondary
endpoint in the placebo, 30 mg YIC and 60 mg YIC groups,
respectively. The response rate for secondary endpoint in the 60 mg
YIC group was comparatively higher than that of the other groups,
though statistical significance had not been reached. However, at the
end of follow-up, a significant difference on HBeAg seroconversion
was found between 60 mg YIC and placebo groups (p=0.03, 2-
tailed). The 95% confidence interval for this difference was 1.5% to
24.1%. In contrast, a statistical significance had not been reached
between 30 mgY I Ca n dp l a c e b og r o u p s .
Furthermore, when applying the GEEs method to estimate the
group and time effects, a significant difference of group effects was
found between the 60 mg group and the placebo group in terms of
the primary endpoint, and response rate calculated by both primary
and secondary endpoints changed significantly over the time in the
placebo, 30 mga n d6 0mgY I Cg r o u p s( p ,0.05) (Table 3).
When the baseline serum HBV DNA and levels of HBeAg from
all secondary responders at the end of follow-up in the three groups
were analyzed, among the 14 patients immunized with 60 mgY I C,
five had HBV DNA$10
7 copies/ml, eight had HBV DNA $10
6
and ,10
7 copies/ml, only one had HBV DNA 10
5 copies/ml. In
contrast, of the 6 patients immunized with alum, five patients had
HBV DNA 10
5 copies/ml, one had HBV DNA $10
6 and ,10
7
copies/ml, none of them had HBV DNA $10
7 copies/ml.
Reversion of HBeAg and rebound of HBV DNA
The incidence of rebound in virus replication and reversion to
serum HBeAg at the end of follow-up were compared among the
three groups. For those responders who reached the secondary
endpoint, none of the patients from either the 60 mg YIC group or
placebo group showed a rebound in virus load nor in reversion to
serum HBeAg. In contrast, four responders in the 30 mg YIC
group showed a virus load rebound to the baseline level and
HBeAg reverted to positive. Interestingly, rebound of viral load
and reversion to serum HBeAg were all from responders who only
reached the primary endpoint at the end of immunization, while
none occurred in those who reached the secondary endpoint,
suggesting that patients who achieved the secondary response at
the endpoint of treatment were unlikely to develop reversion.
Adverse events and severe adverse events
Overall, the most common systematic symptoms were similar for
the three groups. However, more local reactions were found in the
60 mgY I Ca n d3 0mg YIC groups. In the placebo group, the most
common reaction was pain at the injection site, followed by malaise
and fatigue; in the 30 mga n d6 0mg YIC group, the most common
adverse events were pain at the injection site, pruritus and swelling
(Table 4). During study period, eleven patients experienced elevated
ALT levels over ten times the normal level, accompanied by high
levels of serum bilirubin and thus were hospitalized.
The occurrence of serious adverse events calculated according
to the intent-to-treat principle was 5.1% (4/79), 3.6% (3/83), and
Therapeutic HB Vaccine
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respectively (p.0.05). Ten of these were males, while one was
female. The age of patients with SAE varied between 21 and
41years of age. Four occurred after the first injection (2 in placebo
group, 2 in 60 mg YIC group), two occurred after the second
injection (1 in placebo group, 1 in 30 mg YIC group), one occurred
after 5 injections (in 30 mg YIC group), and the other four
appeared after 6 injections (1 in placebo group, 1 in 30 mg YIC
Figure 1. Summary of participants. Footnote: The numbers of SAE patients are those who discontinued treatment, while other SAE patients are
not included in this figure.
doi:10.1371/journal.pone.0002565.g001
Table 1. Characteristics of participants.
Characteristics Placebo group (N=78) 30 mg YIC group (N=81) 60 mg YIC group (N=78)
Age (yr; SD) 27.967.6 28.668.6 28.868.0
Female sex (no. ; %) 19 (24.4) 22 (27.2) 17 (21.8)
Weight (kg; SD) 61.7611.1 62.3610.0 63.769.3
Course of illness, hepatitis B (yr; SD) 6.365.2 6.065.8 6.165.4
Family history, hepatitis B (no.;%) 46 (59.0) 46 (56.8) 46 (59.0)
Alanine aminotransferase (IU/liter; SD) 169.6680.0 162.5674.7 171.8693.4
HBV DNA (log copies/mL; SD) 7.160.9 7.160.9 7.260.8
SD: Standard deviation.
doi:10.1371/journal.pone.0002565.t001
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hospitalized and recovered after treatment without immunomod-
ulating drugs (one patient used antiviral treatment). No deaths
were observed during the study period.
Discussion
In this study,statistical significant differences inthe preset primary
and secondary endpoints among the three groups of patients were
not reached at the end of treatment or of follow up. Nevertheless,
patients immunized with intramuscular injections of 60 mgY I C
showed the highest rates of HBeAg loss (23.1%), HBeAg
seroconversion (21.8%) and suppression of HBV DNA (37.2%) at
the end of follow-up (44 weeks). When one of the primary endpoints
(HBeAg) seroconversion, was compared between 60 mg YIC and
placebo groups at the end of follow-up, statistical significance was
observed (p=0.03). Interestingly, these rates in 60 mg YIC group at
44 weeks markedly surpassed those achieved at 24 weeks, namely,
HBeAg loss (23.1% vs 11.5%), HBeAg seroconversion (21.8%
vs7.7%) and suppression of HBV DNA (37.2% vs26.9%) (Table 2).
An important difference between YIC as an active immunothera-
peutic vaccine versus passive immunotherapies such as using
interferon, thymosin et al for treatment, is that, active immunother-
apeutic approach functions through inducing immune responses in
the patients; while in passive immunotherapeutic approaches, the
immunological modulating products are repeatedly introduced into
patients, and thus continuously providing the patients with the
necessary immunological modulating products. The former ap-
proach needs onlyfew injections at relatively long intervals,while the
latterneeds repeated injectionsofproducts to immunomodulate host
immune responses. Therefore, it is not surprising, a late and
sustained response versus YIC immunization was observed in a
subpopulation of patients.
Though the response rates with respect to the secondary
endpoints in the 60 mg YIC group were comparatively higher than
that of the other groups, due to the unexpected rates of HBeAg
seroconversion and suppression of serum HBV DNA in the alum
immunized group, statistical significance was not reached.
Nevertheless, after adjusting the dependence among repeated
observations made on the same patient, a significant change of
response rate over the study period was detected in the placebo,
30 mg and 60 mg YIC groups, with respect to either primary or
secondary endpoints (p,0.05) (Table 3).
It was intriguing that only alum immunization resulted in a
decrease of HBV viral load and seroconversion of HBeAg in some
patients. As shown in the analysis of patients who reached secondary
response at the end of follow-up, the baseline serum HBV DNA in
patients who responded to alum alone immunization predominantly
were those who had lower levels of serum HBV DNA (10
5 copies/
mL). Whether this phenomenon was due to spontaneous sero-
conversion in patients needs to be considered. Ideally, to include a
group of patients without injections as additional control in the study
Table 2. Virologic response at the end of treatment and the end of follow-up.
End of treatment (week 24) End of follow-up (week 44)
Placebo
group
(N=78)
30 mgY I C
group
(N=81)
60 mgY I C
group
(N=78) p value
Placebo
group
(N=78)
30 mgY I C
group
(N=81)
60 mgY I C
group
(N=78) p value
HBeAg loss (No.;%) 8 (10.3) 9 (11.1) 9 (11.5) 0.99 9 (11.5) 11 (13.6) 18 (23.1) 0.13
Presence of anti-HBe antibody (No.;%) 9 (11.5) 15 (18.5) 15 (19.2) 0.65 10 (12.8) 18 (22.2) 23 (29.5) 0.06
HBeAg seroconversion
* (No.;%) 6 (7.7) 8 (9.9) 6 (7.7) 0.97 7 (9.0) 10 (12.3) 17 (21.8) 0.08
HBV DNA 13 (16.7) 21 (25.9) 21 (26.9) 0.46 28 (35.9) 21 (25.9) 29 (37.2) 0.28
.2log decrease (No.;%)
Primary endpoint
^ (No.;%) 18 (23.1) 22 (27.2) 26 (33.3) 0.63 31 (39.7) 28 (34.6) 35 (44.9) 0.39
Secondary endpoint
$ (No.;%) 3 (3.8) 8 (9.9) 6 (7.7) 0.59 6 (7.7) 7 (8.6) 14 (17.9) 0.14
*: 95% confidence interval (2-tailed) for the difference of response rate at week 44 between 60 mg YIC and placebo groups was 1.5% to 24.1%; it was 26.3% to 13.0%
between 30 mg YIC and placebo groups.
^: 95% confidence interval (2-tailed) for the difference of response rate at week 44 between 60 mg YIC and placebo groups was 210.4% to 20.6%; it was 220.2% to 9.8%
between 30 mg YIC and placebo groups.
$: 95% confidence interval (2-tailed) for the difference of response rate at week 44 between 60 mg YIC and placebo groups was 20.2% to 20.7%; it was 27.6% to 9.5%
between 30 mg YIC and placebo groups.
doi:10.1371/journal.pone.0002565.t002
Table 3. Repeated measures analysis for time and group effects controlling by baseline ALT and HBV DNA.
Group Primary endpoint Secondary endpoint
OR (95% confidence interval) p value OR (95% confidence interval) p value
30 mg YIC group vs placebo group 0.9 (0.5–1.4) 0.52 1.3 (0.5–3.6) 0.60
60 mg YIC group vs placebo group 1.7 (1.0–2.7) 0.04 2.2 (0.9–5.4) 0.09
Week 12 vs Week 44 0.3 (0.2–0.5) ,0.0001 0.3 (0.2–0.6) 0.0006
Week 24 vs Week 44 0.5 (0.4–0.7) ,0.0001 0.6 (0.4–0.9) 0.01
Week 36 vs Week 44 0.7 (0.6–1.0) 0.04 0.6 (0.4–1.0) 0.04
doi:10.1371/journal.pone.0002565.t003
Therapeutic HB Vaccine
PLoS ONE | www.plosone.org 5 July 2008 | Volume 3 | Issue 7 | e2565maywellclarifythisissue.However,duetoethicalconcern,aswellas
double blinding principle, such study design has not been approved.
UsingthedatafromapreviousstudybyYuenetalasareference,the
one year HBeAg sero-conversion rate in patients treated with IFN-a
and untreated patient was 21.1% and 2.2% [25]. In another clinical
trial of lamivudine treatment, at the end of one year, the HBeAg
sero-conversion rate was 8.3% in the treated group [26]. These
studies suggested that the 21.8% of HBeAg seroconversion rate in
Chinese patients observed in this study most likely was not due to
spontaneous sero-conversion. Besides, by pair-wise comparison,
significance of HBeAg seroconversion rate was only found between
the 60 mg YIC and the placebo groups, other than between the
30 mg YIC and the placebo groups, which further supported the
previous finding was not due to spontaneous seroconversion. As for
the 10 patients in the 60 mg YIC immunized group who only
reached primary responses at the end of treatment, attained
secondary responses during follow-up, could be due to a late
response to YIC immunization, however, spontaneous HBeAg sero-
conversion should be excluded. Recently, it was reported that
immune complex-loaded dendritic cells were superior to soluble
immune complexes as an anti-tumor vaccine in animals [27],
Furthermore, antigen-antibodyimmune complexes were reported to
empower dendritic cells to efficiently prime specific CD8+ CTL
responses in vivo [28]. These studies strengthened our confidence in
using immune complexes as a therapeutic vaccine for persistent
infections. Compared to passive immunotherapy, we consider active
immunization by YIC is a simple-to-use, less expensive and
promising therapeutic vaccine in a subpopulation of chronic
hepatitis B patients.
Regarding the effect of alum, it was reported that alum alone can
promote B cell activation in mice, which could bypass the priming
effect needed for B cell responses [29]. Whether alum also can
induce T cell responses is still under discussion [30]. One may
speculate that immunization with alum alone activated the B cells in
some chronic hepatitis B patients and when these B cells came across
the circulating HBsAg in these patients, a low level of immune
responses to HBsAg might be triggered and eventually could lead to
decrease in virus load, and /or sero-conversion of HBeAg.
Patients who developed severe adverse events were distributed
almost equally in the three groups. It was surprising that three
patients immunized with only alum developed severe adverse
events, and two of them even developed severe adverse events after
only one injection. The severe adverse events in these two patients
were verified by highly elevated ALT levels attaining 937 U/L and
818 U/L with TB 111.6 mmol/L and 54.8 mmol/L respectively.
In the forthcoming phase III clinical trial, not only the therapeutic
efficacy of YIC should be evaluated, but also severe adverse events
will be closely monitored and investigated.
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